Aparna R. Parikh

Jan 17, 2025 | onclive.com | Aparna R. Parikh

CommentaryVideoJanuary 17, 2025Author(s):Fact checked by:,Aparna Parikh, MD, discusses the importance of upfront molecular testing in patients with metastatic colorectal cancer. “Molecular testing is now considered to be standard of care at the time of diagnosis for mCRC.

Nov 7, 2024 | onclive.com | Aparna R. Parikh

CommentaryVideoNovember 7, 2024Author(s):Aparna Parikh, MD, discusses currently available treatment options for patients with HER2-positive colorectal cancer.

Aug 21, 2024 | onclive.com | Aparna R. Parikh

CommentaryVideoAugust 21, 2024Author(s):Aparna Parikh, MD, discusses the rationale for adding ERAS-007 to the BEACON regimen in BRAF V600E–mutated metastatic colorectal cancer.

Jun 26, 2024 | onclive.com | Aparna R. Parikh

CommentaryVideoJune 26, 2024Author(s):Aparna Parikh, MD, discusses outcomes from the HERKULES-3 trial in BRAF V600E–mutated metastatic colorectal cancer.

Mar 1, 2024 | jitc.bmj.com | Heinz-Josef Lenz |Aparna R. Parikh |David R. Spigel |Allen L. Cohn

DiscussionPhase 2 results from the CheckMate 9X8 trial did not demonstrate a statistically significant improvement in median PFS with nivolumab plus SOC versus SOC in the first-line treatment of patients with mCRC. The PFS curves overlapped before separating at approximately 12 months; nivolumab plus SOC showed numerically higher PFS rates after 12 months compared with SOC. PFS subgroup analyses showed a numerical trend favoring nivolumab plus SOC across multiple subgroups (HR<1).